CoChat

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

Jacob, S., Rabbia, M., Meier, M. K., Hauptman, J. · 2009 · Diabetes, Obesity and Metabolism
Cited by 72

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background: Both obesity and type 2 diabetes are associated with increased morbidity and mortality. Published data suggest that orlistat 120 mg, a lipase inhibitor used to treat obesity, may improve glycaemic parameters through weight loss–independent effects. Aim: To investigate the effect of orlistat 120 mg on weight loss, and assess whether changes in glycaemic parameters [fasting plasma glucose (FPG) and haemoglobin A 1c (HbA 1c )] are independent of weight loss. Methods: This retrospective analysis of pooled data from seven multicentre, double‐blind, placebo‐controlled studies involved overweight or obese patients with type 2 diabetes (aged 18–70 years). Patients were required to have a body mass index of 27–43 kg/m 2 , HbA 1c of 6.5 to <13%, and stable weight for ≥3 months. Subjects received orlistat 120 mg tid or placebo for 6 or 12 months. Results: A total of 2550 overweight or obese patients with type 2 diabetes were enrolled and randomized to treatment with orlistat 120 mg tid (n = 1279) or placebo (n = 1271). For the whole population, patients treated with orlistat 120 mg had significantly greater mean decreases in FPG compared with placebo‐treated patients (−1.39 mmol/l vs. −0.47 mmol/l; p < 0.0001). In addition, orlistat 120 mg provided significantly larger mean decreases in HbA 1c compared with placebo (−0.74% vs. −0.31%; p < 0.0001). For patients with minimal weight loss (≤1% of baseline body weight), orlistat 120 mg still provided a significantly greater decrease in the least squares mean value for both FPG (−0.83 mmol/l vs. ±0.02 mmol/l; p = 0.0052) and HbA 1c −0.29% vs. ±0.14%; p = 0.0008). This suggested that the improvement of glycaemic control with orlistat 120 mg was independent of weight loss. Using linear regression analysis, improvement in glycaemic control (FPG and HbA 1c ) with orlistat 120 mg was less strongly correlated with weight loss than for placebo. Conclusion: Orlistat 120 mg appears to improve glycaemic control more than would be predicted by weight loss alone in overweight or obese patients with type 2 diabetes. Postulated mechanisms underlying this effect include an improvement of insulin sensitivity, a slower and incomplete digestion of dietary fat, reduction of postprandial plasma non‐esterified fatty acids, decreased visceral adipose tissue, and stimulation of glucagon‐like peptide‐1 secretion in the lower small intestine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00970.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 40

  1. 10.1001/jama.282.16.1523 · DOI · Paper page
  2. 10.1136/bmj.324.7331.192c · doi:10.1136/bmj.324.7331.192c
  3. 10.2337/diacare.23.10.1499 · DOI · Paper page
  4. 10.1210/rp.59.1.207 · DOI · Paper page
  5. 10.1007/s001250051172 · DOI · Paper page
  6. 10.1038/oby.2000.7 · DOI · Paper page
  7. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  8. 10.7326/0003-4819-128-3-199802010-00001 · DOI · Paper page
  9. 10.2337/diacare.22.1.33 · DOI · Paper page
  10. 10.1001/jama.298.2.194 · DOI · Paper page
  11. 10.1007/s11883-008-0009-z · DOI
  12. Guerciolini R, 1997, Mode of action of orlistat, Int J Obes, 21, S12
  13. 10.1046/j.1365-2796.2000.00720.x · DOI · Paper page
  14. 10.2337/diacare.27.1.33 · DOI · Paper page
  15. Expert Committee of the Canadian Diabetes Advisory Board, 1992, Clinical practice guidelines for treatment of diabetes mellitus, Can Med Assoc J, 147, 697
  16. 10.1016/S0149-2918(96)80057-9 · DOI · Paper page
  17. 10.1111/j.1464-5491.2004.01474.x · DOI · Paper page
  18. Jacob S, 2006, Orlistat has positive effects on glycaemic control in type 2 diabetes beyond the improvements produced by weight loss alone, Obes Rev, 7
  19. 10.4158/EP.7.1.44 · DOI
  20. Carpentier A, 1999, Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation, Am J Physiol, 276, E1055
  21. 10.2337/diabetes.49.3.399 · DOI · Paper page
  22. 10.2337/diab.42.11.1567 · DOI · Paper page
  23. 10.1046/j.1464-5491.2002.00823.x · DOI · Paper page
  24. Björntorp P, 1996, The regulation of adipose tissue distribution in humans, Int J Obes, 20, 291
  25. 10.1016/0026-0495(92)90016-4 · DOI · Paper page
  26. 10.1093/ajcn/79.1.22 · DOI
  27. Mendoza‐Guadarrama LG, 2000, Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2, Int J Obes, 24
  28. 10.1046/j.1463-1326.2003.00262.x · DOI · Paper page
  29. 10.1111/j.1464-5491.2005.01723.x · DOI · Paper page
  30. 10.1093/ije/dyi253 · DOI · Paper page
  31. 10.1007/BF02064202 · DOI · Paper page
  32. 10.1152/ajpgi.00411.2005 · DOI
  33. 10.2337/diacare.27.5.1077 · DOI
  34. 10.1210/jc.2003-030199 · DOI · Paper page
  35. 10.1152/ajpgi.00512.2002 · DOI · Paper page
  36. 10.1016/S0016-5085(98)70640-7 · DOI
  37. 10.1136/gut.46.6.774 · DOI
  38. Serrano‐Rios M, 2001, Orlistat efficacy on weight loss in overweight or obese patients with type 2 diabetes mellitus. Spanish randomized clinical trial [abstract], Diabetes, 50
  39. Bonnici F, 2002, Effect of orlistat on bodyweight, glycemic control and cardiovascular risk factors in overweight or obese South African patients with type 2 diabetes [abstract], Diabetes, 51, A412
  40. Derrochanawong C, 2001, Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract], Diabetes, 50

Cited by

See all 72

Metadata

Authors
Jacob, S., Rabbia, M., Meier, M. K., & Hauptman, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2009-02-24
Volume
11
Issue
4
Pages
361-371
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1988187729
Cited by
72
References
17
FWCI
2.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00970.x
The paper
Jacob, S., Rabbia, M., Meier, M. K., & Hauptman, J. (2009). Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00970.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.